Breast Cancer is expected to grow at a CAGR of 2.44% during the forecast period 2016-2020.

Summary of the report:
The breast cancer pipeline is the largest in the pharmaceutical industry, with 1,050 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape. The degree and proportion of breakthrough innovations in this pipeline is exceptional – GBI Research analysis identified 333 first-in-class programs in the breast cancer pipeline, acting on 251 first-in-class molecular targets. This accounts for some 39% of all products with a disclosed molecular target, and is reflective of the high degree of innovation in this indication. This has far-reaching strategic implications for all market participants, as despite the high attrition rate in breast cancer, it is highly likely many of the first-in-class products will reach the market over the coming decade and, will have the opportunity to transform the clinical and commercial landscape.
Potential driving factors behind this market include a very large and growing patient pool, a well-established disease market with a number of strong unmet needs, and the strong understanding of the disease pathophysiology that has developed over the last decade, facilitating the development of novel compounds that may fill the unmet needs.

Check complete report @ http://www.marketintelreports.com/report/gbihc402mr/frontier-pharma-breast-cancer--firstinclass-innovation-clustered-around-growth-factor-signalling-processes

SCOPE:
Some 289 first-in-class products that are currently in development have not yet been involved in licensing or co-development deals, meaning there are numerous opportunities for in-licensing or co-development in this indication, which already has a strong track record of breakthrough innovation yielding highly commercially and clinically successful therapies.

• The report analyzes innovation in breast cancer, in the context of the overall pipeline and current market landscape. In addition, it analyzes the deals landscape surrounding first-in-class products in breast cancer, and pinpoints opportunities for in-licensing.
• A brief introduction to breast cancer, including symptoms, pathophysiology, and an overview of pharmacotherapy and treatment algorithms.
• The changing molecular target landscape between the market and the pipeline, and particular focal points of innovation in the pipeline.
Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target.

• Identification and assessment of first-in-class molecular targets, with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets.
• Assessment of the licensing and co-development deal landscape for breast cancer therapies, and benchmarking of deals involving first-in-class versus non-first-in-class-products.

Get Sample Brochure of the report @ http://www.marketintelreports.com/pdfdownload.php?id=gbihc402mr

Reasons to buy
• Understand the current clinical and commercial landscape, including a comprehensive study of disease pathogenesis, diagnosis, prognosis and the available treatment options available at each stage of diagnosis.
• Visualize the composition of the breast cancer market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed.
• This knowledge allows a competitive understanding of the gaps in the current market.
Analyze the breast cancer pipeline, stratified by stage of development, molecule type and molecular target.
• Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
• Identify commercial opportunities in the breast cancer deals landscape by analyzing trends in licensing and co-development deals, and producing a list of breast cancer therapies that are not yet involved in deals and may be potential investment opportunities.

Order a copy of Breast Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016@ http://www.marketintelreports.com/purchase.php?id=gbihc402mr

About us:
MarketIntelReports (MIR) aim to empower our clients to successfully manage and outperform in their business decisions, we do this by providing Premium Market Intelligence, Strategic Insights and Databases from a range of Global Publishers.
A group of industry veterans who are well experienced in reputed international consulting firms after identifying the sourcing needs of MNCs for market intelligence, have together started this business savior MarketIntelReports.
MIR intends to be a one-stop shop with an intuitive design, exhaustive database, expert assistance, secure cart checkout and data privacy integrated. It curates the list of reports, publishers and studies to ensure that the database is constantly updated to dynamically meet the targeted, specific needs of our clients.
MarketIntelReports currently has more than 10,000 plus titles and 35+ publishers on our platform and growing consistently to fill the “Global Intelligence Demand – Supply Gap”. We cover more than 15 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Building & Construction, Agriculture, Food & Beverages, Banking & Finance, Media and Government, Public Sector Studies.

Contact us:
Sales Manager
Mayur S
2711 Centerville Road, Suite 400,
Wilmington,
Delaware,
19808
United States
www.marketintelreports.com
sales@marketintelreports.com
Telephone: 1-302-684-6088

This release was published on openPR.